Emtricitabine/rilpivirine/tenofovir (Eviplera®)

All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000602
English
Authors' recommendations: Emtricitabine/rilpivirine/tenofovir (Eviplera®) is recommended as an option for use within NHS for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load = 100,000 HIV-1 RNA copies/ml.
Details
Project Status: Completed
Year Published: 2012
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Wales, United Kingdom
MeSH Terms
  • HIV Infections
  • Drug Therapy, Combination
  • Anti-HIV Agents
  • Rilpivirine
  • Emtricitabine, Rilpivirine, Tenofovir Drug Combination
  • HIV
  • Reverse Transcriptase Inhibitors
Contact
Organisation Name: All Wales Medicines Strategy Group
Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name: AWTTC@wales.nhs.uk
Contact Email: AWTTC@wales.nhs.uk
Copyright: AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.